

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/728,665
		Filing Date	December 5, 2003
		First Named Inventor	Satyanarayana MEDICHERLA
		Art Unit	1614
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	12+79 Refs	Attorney Docket Number	219002032800

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Form 1449, 4 pages (in duplicate)
<input checked="" type="checkbox"/> Information Disclosure Statement, 3 pages	<input type="checkbox"/> CD, Number of CD(s) _____	(79) References
<input type="checkbox"/> Certified Copy of Priority Document(s)		Return Postcard
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	CUSTOMER NO. 25225	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP James J. Mullen, III - 44,957
Signature	
Date	April 15, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 15, 2004


Signature: (Rhea Amid)



PATENT
Docket No. 219002032800

CERTIFICATE OF MAILING BY "FIRST CLASS"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on April 15, 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Satyanarayana MEDICHERLA et al.

Serial No.: 10/728,665

Filing Date: December 5, 2003

For: METHODS FOR TREATING
DIABETES

Examiner: Unassigned

Group Art Unit: 1614

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 219002032800. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 15, 2004

Respectfully submitted,

By: 

James J. Mullen, III, Ph.D.

Reg. No. 44,957

Morrison & Foerster LLP

3811 Valley Centre Drive, Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-7940

Facsimile: (858) 720-5125

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 219002032800

Application Number 10/728,665

Applicant

Satyanarayana MEDICHERLA et al.

Filing Date December 5, 2003

Group Art Unit 1614

Mailing Date April 15, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	08/1978	4,107,288	Oppenheim et al.	424	22	
	2.	10/1986	4,619,652	Eckenhoff et al.	604	415	
	3.	09/1992	5,145,684	Liversidge et al.	424	489	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	4.	07/1996	WO 96/21452	PCT			
	5.	07/1996	WO 96/21654	PCT			
	6.	12/1996	WO 96/40143	PCT			
	7.	07/1997	WO 97/25046	PCT			
	8.	10/1997	WO 97/35856	PCT			
	9.	06/1998	WO 98/25619	PCT			
	10.	12/1998	WO 98/56377	PCT			
	11.	12/1998	WO 98/57966	PCT			
	12.	07/1999	WO 99/32110	PCT			
	13.	07/1999	WO 99/32121	PCT			
	14.	07/1999	WO 99/32463	PCT			
	15.	11/1999	WO 99/57101	PCT			
	16.	12/1999	WO 99/61440	PCT			
	17.	12/1999	WO 99/64400	PCT			
	18.	03/2000	WO 00/10563	PCT			
	19.	03/2000	WO 00/17204	PCT			
	20.	04/2000	WO 00/19824	PCT			
	21.	07/2000	WO 00/41698	PCT			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 219002032800	Application Number 10/728,665
	Applicant Satyanarayana MEDICHERLA et al.	
	Filing Date December 5, 2003	Group Art Unit 1614
	Mailing Date April 15, 2004	

	22	11/2000	WO 00/64422	PCT				
	23	11/2000	WO 00/71535	PCT				
	24	01/2001	WO 01/05749	PCT				
	25	02/2001	WO 01/10865	PCT				
	26	05/2001	WO 01/38324	PCT				
	27	09/2001	WO 01/64679	PCT				
	28	09/2001	WO 01/66539	PCT				
	29	09/2001	WO 01/66540	PCT				
	30	01/2002	WO 02/07772	PCT				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	31	Adams et al., Bioorg. Med. Chem. Lett. 8:3111-3116 (1998).
	32	Badger, J. Pharmacol. Exp. Ther. 279:1453-1461 (1996).
	33	Balasa et al., J. Immunology 165:2841-2849 (2000).
	34	Blair et al., J. Biol. Sci. 17:36293-36299 (1999).
	35	Burysek et al., J. Biol. Chem. 277:33509-33517 (2002).
	36	Casteels et al., Transplantation 65:1225-1232 (1998).
	37	Chen et al., Diabetologia 44:325-332 (2001).
	38	Cohen, "Diabetes and Protein Glycation" in: Clinical and Pathophysiologic Relevance, JC Press, Philadelphia, PA (1996).
	39	Collis et al., Bioorg. Med. Chem. Lett. 11:693-696 (2001).
	40	Crump, J. Family Practice 25:78-82 (1987).
	41	Debussche et al., Diabete & Metabolisme (Paris) 20:282-290 (1994).
	42	De Laszlo et al., Bioorg. Med. Chem. Lett. 8:2698 (1998).
	43	Fijen et al., Clin. Exp. Immunol. 124:16-20 (2001).
	44	Gallagher et al., Bioorg. Med. Chem. 5:49-64 (1997).

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 219002032800	Application Number 10/728,665
		Applicant Satyanarayana MEDICHERLA et al.	
		Filing Date December 5, 2003	Group Art Unit 1614
		Mailing Date April 15, 2004	
	45	Goebeler et al., Blood 93 :857-865 (1999).	
	46	Hale et al., J. Immunol. 162 :4246-4252 (1999).	
	47	Hancock et al., Am. J. Patho. 147 :1194-1199 (1995).	
	48	Harris, "Definition and Classification of Diabetes Mellitus and the New Criteria for Diagnosis," pp. 326-334, Table 32-3, in DIABETES MELLITUS, A Fundamental and Clinical Text, LeRoith D. et al. Eds., 2 nd ed. (2000).	
	49	Heinze and Thon, Pediatrician 12 :208-212 (1985).	
	50	Herlaar and Brown, Molec. Med. Today 5 :439-447 (1999).	
	51	Hosker and Turner, Lancet 18 :633-635 (1982).	
	52	Jackson, J. Pharmacol. Exp. Ther. 284 :687-692 (1998).	
	53	Keymeulen and Somer, Acta Clinica Belgica 48 :86-95 (1993).	
	54	Kimble et al., Endocrinol., 136 :3054-3061 (1995).	
	55	Kumar et al., Biochem. Biophys. Res. Comm. 235 :533-538 (1997).	
	56	Lee et al., Immunopharmacology 47 :185-201 (2000).	
	57	Mahon et al., Ann. N.Y. Acad. Sci. 696 :351-363 (1993).	
	58	Makino et al., Exp. Animal 29 :1-13 (1980).	
	59	McLay et al., Bioorg. Med. Chem. 9 :537-554 (2001).	
	60	Miyazaki et al. Clin. Exp. Immuno. 60 :622-630 (1985).	
	61	Mori et al., Diabetologia 29 :244-247 (1986).	
	62	Palmer and McCulloch, Diabetes 40 :943-947 (1990).	
	63	Pavlovic et al., Eur. Cytokine Netw. 11 :267-274 (2000).	
	64	Poste et al., Meth. Cell Biol. 14 :33 (1976).	
	65	Rapoport et al., J. Exp. Med. 177 :1221-1227 (1993).	
	66	Ravelli, Curr. Opin. Rheumatol. 14 :548-552 (2002).	
	67	Revesz et al., Bioorg. Med. Chem. Lett., 10 :1261-1264 (2000).	
	68	Rogers and Giembycz, Drug Discov. Today 3 :532-535 (1998).	
	69	Ryu et al., J. Clin. Invest. 108 :63-72 (2001).	
	70	Salomon et al., Immunity 12 :431-437 (2000).	
	71	Shapiro et al., Diabetologia 45 :224-230 (2002).	
	72	Sprinkel et al., Eur. Cytokine Netw. 12 :331-339 (2001).	
	73	Sugihara et al., Histol. Histopathol. 4 :397-404 (1989).	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

